Cerity Partners
ALNY icon

Cerity Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cerity Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.89M Sell
16,252
-4,004
-20% -$1.21M 0.01% 1113
2026
Q1 		$6.7M Sell
20,256
-4,322
-18% -$1.47M 0.01% 883
2025
Q4 		$9.77M Sell
24,578
-2,851
-10% -$1.26M 0.01% 645
2025
Q3 		$12.5M Buy
27,429
+17,316
+171% +$7.05M 0.02% 497
2025
Q2 		$3.3M Sell
10,113
-4,529
-31% -$1.25M 0.01% 997
2025
Q1 		$3.95M Buy
14,642
+1,117
+8% +$287K 0.01% 823
2024
Q4 		$3.24M Buy
13,525
+506
+4% +$133K 0.01% 895
2024
Q3 		$3.58M Buy
13,019
+7,445
+134% +$1.94M 0.01% 848
2024
Q2 		$1.35M Buy
5,574
+2,382
+75% +$376K ﹤0.01% 1094
2024
Q1 		$477K Buy
+3,192
New +$532K ﹤0.01% 1622
2023
Q1 		– Sell
-1,070
Closed -$254K – 1850
2022
Q4 		$254K Buy
+1,070
New +$228K ﹤0.01% 1219

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's ALNY Position: Q2 2026 in Review

Cerity Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q2 2026, selling an estimated $1.21M and leaving 16,252 shares worth $4.89M. The position accounts for 0.01% of the portfolio, ranked #1113.

Cerity Partners first reported a position in ALNY in Q4 2022 and has held it in 11 quarters since. The position peaked at $12.5M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cerity Partners held 16,252 shares of Alnylam Pharmaceuticals worth $4.89M as of Q2 2026.
  • Cerity Partners sold 4,004 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.21M.
  • Alnylam Pharmaceuticals made up 0.01% of Cerity Partners's portfolio in Q2 2026, its #1113 holding.
  • Cerity Partners first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • Cerity Partners's Alnylam Pharmaceuticals position peaked at $12.5M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.